The DOI matches its Crossref record.
Sex-Related Difference in the Growth of Prolactinomas: A Clinical and Proliferation Marker Study
Abstract
Prolactinomas in women commonly present as small intrasellar tumors, but are usually much larger in men. This discrepancy has generally been attributed to differences in the delay before diagnosis. However, studies comparing clinical and pathological correlates of growth of these tumors in both sexes are lacking. We conducted a retrospective study comparing 45 men and 51 women bearing prolactinoma to determine whether the predominance of large tumors in men was due to a delay in diagnosis or, rather, to a fundamental sex-related difference in tumor growth. Basal PRL levels (mean +/- SEM, 2789 +/- 573 ng/mL) and mean tumor diameter (26 +/- 2 mm) were significantly higher in men than in women (292 +/- 74 ng/mL and 10 +/- 1 mm, respectively; P < 0.001), but were not correlated to the age at diagnosis or the duration of symptoms. Giant tumors (n = 8) occurred in males only. The frequencies of bromocriptine-resistant tumors (30 vs.5%; P < 0.01) and invasive macroadenomas (52 vs.27%; P < 0.001) were significantly greater in men than those in women. Lastly, macroprolactinomas in males exhibited higher indexes of proliferating cells by Ki-67 immunoreactivity (2.6 +/- 1.1% of positive nuclei) than did similar tumors in female patients (0.4 +/- 0.2%; P = 0.08). We conclude that the predominance of large prolactinomas in men is due to a high frequency of rapidly growing tumors, which are often invasive and frequently bromocriptine resistant.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Advances in the Treatment of Prolactinomas
Gillam, M. P., Molitch, M. E., Lombardi, G., & Colao, A. (2006) · Endocrine Reviews · doi:10.1210/er.2005-9998 · Cited by 824
Pituitary-Tumor Endocrinopathies
Melmed, S. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1810772 · Cited by 604
HYPOPRONOS, T. M. O., Trouillas, J., Roy, P., Sturm, N., Dantony, E., Cortet-Rudelli, C., Viennet, G., Bonneville, J.-F., Assaker, R., Auger, C., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1084-y · Cited by 545
Cabergoline in the Treatment of Hyperprolactinemia: A Study in 455 Patients
Verhelst, J., Abs, R., Maiter, D., van den Bruel, A., Vandeweghe, M., Velkeniers, B., Mockel, J., Lamberigts, G., Petrossians, P., Coremans, P., et al. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.7.5810 · Cited by 449
Angiogenesis in Endocrine Tumors
Turner, H. E., Harris, A. L., Melmed, S., & Wass, J. A. H. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0008 · Cited by 275
Metadata
- Authors
- Delgrange, E.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1997-07-01
- Volume
- 82
- Issue
- 7
- Pages
- 2102-2107
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W4248421755
- Cited by
- 181
- References
- 0
- FWCI
- 3.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sex-Related Difference in the Growth of Prolactinomas: A Clinical and Proliferation Marker Study. https://app.cochat.ai/papers/10.1210/jc.82.7.2102
- The paper
- Delgrange, E. (1997). Sex-Related Difference in the Growth of Prolactinomas: A Clinical and Proliferation Marker Study. Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.82.7.2102
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.